Allogeneic stem cell transplantation for adult acute leukaemia in CR1 and CR2 with a novel myeloablative conditioning regimen incorporating daily intravenous busulfan, fludarabine, 400 cGy total body irradiation and low-dose antithymocyte globulin  by Russell, J. et al.
induction chemotherapy (cyclophosphamide, daunorubicin, vin-
cristine and MTX i.t.). After induction all patients had to receive a
HAM consolidation course (HD-AraC 3 g/m2 every 12 hours, days
1-4; mitoxantrone 10 mg/m2, days 5-7 and MTX i.t.). Patients in
CR received two courses of MA consolidation (MTX 1.5 g/m2 day
1 and l-asparaginase 104 IU/m2 day 2), and then underwent allo-
SCT or patients without a donor were randomized either to re-
ceive autologous stem cells from peripheral blood or high main-
tenance therapy. The median follow-up was 4.9 years. Between
1998 and 2003, a total of 325 pts entered the study. The median
age was 32 yrs range 15-72 yrs. In 248 (76%) patients CR1 was
reached and 227 of them were HLA typed; 100 had an identical
sibling donor and 127 had no sibling donor. Allo-SCT was per-
formed in 69 (69%) pts and auto-SCT or high maintenance ther-
apy in 58 (46%). The 5-year DFS of pts with a donor vs pts without
a donor was 41.8% vs. 35.5% , P  .40, hazard ratio 0.86, 95% CI
0.61-1.22). The relapse incidence was signiﬁcantly lower (37.3%
vs. 58.8% P  .004) and treatment related mortality (TRM) was
signiﬁcantly higher (20.9% vs. 5.7%, P  .0005) in the donor
group compared to the no donor group. Five-year survival in pts
with and without the donor was 43.0% and 36.9% respectively. For
pts50 years of age 199 of them were HLA-typed; 91 had a donor
and 108 had no sibling donor. The 5-yr DFS rate in the donor vs
no donor group was 42.2% vs. 36.2%, P  .36, hazard ratio 0.84
95% CI 0.58-1.22). Relapse rate was signiﬁcantly lower and TRM
was signiﬁcantly higher in the donor versus no donor group.
Five-year survival for patients with and without a donor was 43.9%
and 37.4% respectively (P  .58), hazard ratio 0.90 (95% CI
0.61-1.32). In conclusion, in the EORTC ALL-4 trial, the inten-
tion to treat analysis shows that DFS and survival rate for al-
lografted pts younger than 50 years of age were not signiﬁcantly
different compared to those receiving auto-SCT or high mainte-
nance. High TRM (20%) remains the main problem of allograft-
ing.
13
THE FEASIBILITY OF CONDITIONING REGIMEN OF FLUDARABINE, ATG,
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TRANSPLANTATION
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Hematopoietic Stem Cell Transplantation Center, The Catholic Univer-
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Background: High dose (HD) cyclophosphamide (CY, 200 mg/
kg) plus ATG seems to be accepted as standard conditioning
regimen in HLA-matched sibling stem cell transplantation (SCT)
for severe aplastic anemia (SAA). However, HD CY causes serious
cardiac toxicity in some cases which may lead to death within a few
weeks. To avoid HD CY-associated cardiac toxicity we underwent
HLA-matched sibling SCT using ATG, reduced CY to half dose
with incorporation of ﬂudarabine. Methods: Between March 2002
and August 2005, consecutive twenty-six patients with adult SAA
(six patients were AA/PNH syndrome) received matched sibling
SCT. The median age of patients was 41 (21-52) and median
interval between Dx and SCT was 30 months (1-352). The median
number of transfusions prior to SCT was 34 units (4-680). Ten
patients (38%) had a history of IST before SCT. The conditioning
regimen consisted of ﬂudarabine (30 mg/m2/day, 6 days), cyclo-
phosphamide (50 mg/kg/day, 2 days) and ATG (2.5 mg/kg/day, 4
days, IMTIX-SangStat). Stem cell sources were BM plus CD34-
selected PBSC (n 9), BM (n 14), or PBSC (n 3). All patients
received of cyclosporine and methotrexate as GVHD prophylaxis.
Results: The median dose of CD34 cells infused was 3.6 
106/kg (1.2-11.9). All patients achieved successful sustained en-
graftment, and the median time for ANC and platelet to reach
0.5  109/L and 20  109/L was 12 (6-16) and 18 (10-23) days,
respectively. None of the patients developed cardiac toxicity or
regimen-related toxicities. One patient developed delayed graft
failure, but achieved successful engraftment after second SCT
using TNI  ATG. The incidence of acute GVHD (more than
grade II) was 8% (n 2) and none developed chronic GVHD. The
incidence of CMV infection requiring preemptive treatment was
38% (n  10). Only one patient died of hepatic failure due to
reactivation of chronic hepatitis C with hepatic GVHD posttrans-
plant 3 months. PNH clone measured by ﬂow cytometry disap-
peared posttransplant in 6 PNH patients. With median follow up
of 12 months (2-41), the estimated probability of survival at 2 years
was 96%. Conclusions: These data demonstrate that the condi-
tioning regimen used in this study is feasible for patients with SAA
who receive matched sibling SCT. Of note, the observations of
successful engraftment as well as lesser acute GVHD and no
chronic GVHD suggest that a ﬂudarabine-based regimen has more
potent immunomodulatory activity.
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RESPIRATORY VIRUS INFECTION AMONG HEMATOPOIETIC CELL
TRANSPLANTATION (HCT) RECIPIENTS: QUANTITATIVE VIRAL LOAD
IN SYMPTOMATIC AND ASYMPTOMATIC INFECTIONS
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Morrow, R.1,2,3, Cent, A.1,2,3, Boeckh, M.2,3 1Children’s Hospital &
Regional Medical Center, Seattle, WA; 2University of Washington,
Seattle, WA; 3Fred Hutchinson Cancer Research Center, Seattle, WA.
Background: Inﬂuenza (ﬂu), respiratory syncytial virus (RSV), and
parainﬂuenza virus (PIV) may cause serious respiratory disease fol-
lowing HCT, with infection rates of 2-10%. The extent of infection
and disease due to human metapneumovirus (MPV) is largely un-
known. We assessed viral infectious episodes after HCT using con-
ventional and quantitative molecular detection. Methods: Weekly
symptom surveys, nasal washes and throat swabs were collected from
HCT recipients for 100 days post-HCT between Jan. 2001-June
2004. Samples were tested by culture and DFA for RSV, PIV and Flu,
and by RT-PCR for RSV, PIV, MPV, and ﬂu (detection limit 1100
copies/ml). Longitudinal analysis was performed for patients with5
serial samples or a positive test or death. Results:Of 119 patients, 29
had 31 (26%) separate infectious episodes due to RSV (5), PIV (16),
MPV (6), ﬂu (3), RSV and ﬂu (1). Median time to viral detection was
48 (range 3-96) days after HCT; median duration of viral shedding
was 14 (range 5-42) days in 19 evaluable episodes. Six patients with
PIV remained asymptomatic at the time of positivity, conventional
testing was negative in 5. No asymptomatic shedding of RSV, MPV
or ﬂu was found. PCR testing nearly doubled ﬁrst identiﬁcation of
RSV and PIV infectious episodes: 11 were detected by PCR plus
conventional methods (in 2 patients, PCR detection preceded con-
ventional methods) and 9 were detected by PCR alone. Median virus
copy number in samples from asymptomatic weeks (2.3 104 copies/
ml) differed from samples from symptomatic weeks (8.6 105 copies/
ml; P value .004). Similarly, viral load in samples from patients with 0
or 1 symptoms (2.4  104 copies/ml) was signiﬁcantly lower com-
pared with patients that reported 	1 symptom (1.8  106; P value
.001). PIV was the only virus that showed a lower viral load in patients
with 0 or 1 symptoms compared with 	1 (P value .04). Conclusion:
Both symptomatic and asymptomatic viral shedding among allogeneic
HCT recipients were detectable using virus-speciﬁc molecular test-
ing. Utilization of PCR viral detection methods increased yield of
detectable episodes. PIV infections were more likely to be transiently
asymptomatic than RSV, MPV, or ﬂu. Asymptomatic shedding of
PIV provides a possible explanation of why infection control pro-
grams emphasizing symptoms are highly effective against RSV but
often not versus other viruses such as PIV. These data may guide
implementation of more effective diagnosis and infection control
strategies.
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ANTITHYMOCYTE GLOBULIN
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Intravenous (IV) busulfan (BU) gives more predictable exposure
than the oral form and is easier to administer once daily than the
conventional four times daily schedule. Fludarabine is immuno-
suppressive, antileukaemic and perhaps better tolerated than cy-
clophosphamide. Low-dose pretransplant ATG appears to reduce
morbidity and mortality of graft-versus-host disease (GVHD). A
conditioning regimen incorporating these agents appears well tol-
erated and adding a low dose of total body irradiation (TBI) does
not seem to increase non-relapse mortality. This regimen was
given to a total of 64 acute leukemia patients (pts) aged 18-63
(median 40) years of whom 28 (44%) had ALL or lymphoblastic
lymphoma (n  2) in CR1 (n  22) or CR2 (n  6), and 36 (66%)
had AML (25 CR1, 11 CR2). Donors were matched siblings
(MRD) for 31 (48%) and alternate donors (AD, 28 unrelated and
5 mismatched related) for 33 (52%). Cell source was blood in all
MRD and 26 (76%) AD pts. All pts received ﬂudarabine 50 mg/m2
on days 6 to 2 and IV BU (Busulfex, ESP Pharma) at a
“myeloablative” dose of 3.2 mg/kg daily days 5 to 2 inclusive
and TBI 200 cGy  2 on day 1 or 0. Prophylaxis for GVHD was
cyclosporine A, “short course” methotrexate with folinic acid and
Thymoglobulin (Genzyme) 4.5 mg/kg in divided doses over 3
consecutive days pretransplant ﬁnishing day 0. Follow-up of sur-
vivors is 3-64 months, median 20. After MRD and AD transplants
the incidence of acute GVHD grade II-IV was 11  6% vs 35 
9% (P  .047), acute GVHD grade III-IV was 0% vs 10  6%
(P  .09) and chronic GVHD was 46  10% vs 73  9% (P  ns)
respectively. There were 3 transplant-related deaths, only in ALL
patients, one each from acute GVHD, pneumonitis and PTLD
giving an overall TRM of 5  3%. Of 6 relapsing pts with ALL 4
are in a further remission after a second myeloablative transplant
(3) or chemotherapy and DLI (1), all have chronic GVHD. Four
AML pts died from relapse. Projected 2-year disease-free survival
and survival respectively is 72  9% and 80  8% for ALL, 87 
6% and 87  6% for AML. For the combined group the corre-
sponding ﬁgures are 80  8% and 89  6% for MRD and 78 
8% and 78  8% for AD transplants respectively (P  ns). This
regimen appears relatively well tolerated and gives equivalent ﬁnal
outcomes from MRD and AD. If these results can be conﬁrmed the
combination deserves study in children with acute leukemia in
whom the toxicity of higher doses of TBI could be avoided.
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COMPARISON OF METHOTREXATE- VERSUS SIROLIMUS-CONTAINING
GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS REGIMENS AFTER MY-
ELOABLATIVE STEM CELL TRANSPLANTATION
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Alyea, E.P.1, Antin, J.H.1, Lee, S.J.1 1Department of Medical Oncology,
Dana-Farber Cancer Institute and Brigham and Women’s Hospital,
Boston, MA; 2Department of Biostatistical Science, Dana-Farber Cancer
Institute, Boston, MA.
Background: Graft-versus-host disease (GvHD) is a serious
complication after allogeneic hematopoietic stem cell transplanta-
tion (HSCT). Methotrexate in combination with a calcineurin
inhibitor (CM) is considered standard GvHD prophylaxis. Studies
suggest that sirolimus in combination with a calcineurin inhibitor
(SC) is effective in preventing GvHD and minimizing transplant-
related morbidity and mortality. Method: A total of 159 patients
with hematological diseases underwent myeloablative HLA-
matched HSCT with either CM (n 97) or SC (n 62) as GvHD
prophylaxis at the Dana-Farber Cancer Institute between June
2000 and December 2004 using Cytoxan and TBI conditioning.
Inpatient costs for the ﬁrst transplant year of 94 CM and 47 SC
recipients were obtained. We compared inpatient costs and clinical
outcomes for the ﬁrst transplant year between the two different
GvHD prophylaxis groups by use of univariate and multivariate
analyses. Results: CM recipients were more likely to have unre-
lated donors, BM grafts, and to be transplanted in earlier years than
SC recipients. In univariate analysis, the SC regimen was associ-
ated with faster engraftment (13 days vs 17 days, P  .01), less
grade II to IV acute GvHD (18% vs 37%, P .01) and better DFS
(71% vs 52%, P  .01) and OS (72% vs 53%, P  .01). Days of
initial hospitalization and costs within the ﬁrst year were lower for
SC in the univariate analysis (27 days vs 33 days, P  .01, $101697
vs $110081, P  .03, respectively) but not in the multivariate
analysis (ratio (CM vs SC) 0.99, P  .91, ratio 1.14, P  .30,
respectively). Use of an unrelated donor was the only signiﬁcant
predictor of high costs considering baseline patient characteristics.
In contrast, grade II to IV aGvHD, late engraftment, and in-
hospital death were the signiﬁcant factors associated with high
costs considering both baseline patient characteristics and post-
transplant events. Conclusion: Both OS and DFS in the SC group
were higher in the multivariate analysis, probably due to early
engraftment and reduced incidence of grade II to IV aGvHD seen
in SC group. However, we could not detect the impact of GvHD
prophylaxis on inpatient costs for the ﬁrst transplant year. The SC
regimen is a promising alternative to CM and larger multi-center
randomized trial is planned through the NIH-funded Clinical
Trials Network.
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VALIDATION OF THE PREDICTIVE POWER OF THE HEMATOPOIETIC
CELL TRANSPLANTATION-COMORBIDITY INDEX (HCT-CI) FOR NON-
RELAPSE MORTALITY (NRM) AND SURVIVAL AFTER ALLOGENEIC HCT
Sorror, M.L.1, Giralt, S.2, Sandmaier, B.1,3, Maris, M.1,3,
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The HCT-CI proved to be a sensitive tool to capture pretrans-
plant comorbidities among patients (pts) given allogeneic HCT at
FHCRC (Blood 2005;106:2912). We sought to validate the effec-
tiveness of the HCT-CI in predicting NRM and survival at an-
other institution (MDACC) and compare its performance to those
of other comorbidity indices. For this purpose, pretransplant co-
morbidities were assessed in pts with acute myeloid leukemia in
ﬁrst remission from FHCRC (n  137) and MDACC (n  70) by
two independent investigators. Comorbidities were scored using
HCT-CI, Charlson comorbidity index (CCI), and the adult co-
morbidity evaluation (ACE-27, a recent modiﬁcation of the
Kaplan-Feinstein Index). Conditioning included myeloablative
(78% and 69% of FHCRC and MDACC pts, respectively) or
reduced intensity regimens. Donor grafts were from related (66%
and 86% of FHCRC and MDACC pts, respectively) or unrelated
donors. Stem cell source was marrow (28% and 60% of FHCRC
and MDACC pts, respectively) or G-PBMC. Among the 207 pts,
35%, 29%, and 36%, respectively, had HCT-CI scores of 0 vs 1-2
vs 3; 83%, 9%, and 8%, respectively, had CCI scores of 0 vs 1 vs
2; and 56%, 28%, and 16%, respectively, had ACE-27 scores of
0 vs 1 vs2. HCT-CI scores of 1-2 and3 were found in 33% and
25% FHCRC pts and 20% and 59% MDACC pts. Cumulative
incidences of 2-year NRM were 5%, 7%, and 24%, respectively,
among FHCRC pts with HCT-CI scores of 0 vs 1-2 vs3 and 7%,
14%, and 31% among their MDACC counterparts. Unadjusted
hazard ratios (HR) for NRM were 1.11 and 4.3 for HCT-CI scores
of 1-2 and 3 among FHCRC pts compared to 2.41 and 5.72
among MDACC pts. Similarly, HR for worse survival were 2.47
and 6.21 for HCT-CI scores of 1-2 and 3 among FHCRC pts
compared to 2.18 and 2.73 among MDACC pts. In multivariable
regression analyses, HCT-CI scores showed the highest prediction
for NRM (HR 5.13, P  .001) and worse survival (HR 4.96, P 
.0001) compared to CCI scores (P  .2 and .05, respectively) and
ACE-27 scores (P .03 and .002, respectively). These results were
further validated separately at each institution (Table 1), where
higher HCT-CI scores showed the highest HR predicting of NRM
and worse survival among FHCRC and MDACC pts compared to
other risk factors. Results conﬁrm the ability of HCT-CI to predict
post-HCT outcomes. The HCT-CI identiﬁed more pts with co-
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